Puma Biotechnology Announces Underwriters’ Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million  
10/22/2012 9:37:35 AM

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE:PBYI), a development stage biopharmaceutical company, announced that the underwriters for its public offering of 7,500,000 shares of its common stock at $16.00 per share have elected to exercise in full their option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 1,125,000 shares is expected to take place concurrently with the closing for the initial purchase of 7,500,000 shares on October 24, 2012, subject to customary closing conditions.